Glenmark Makes Progress On Favipiravir Clinical Trials
FabiFlu Could Prevent Patients From Progressing To ARDS
The Phase III clinical trials of Glenmark’s FabiFlu demonstrate that the oral antiviral could prevent mild and moderate Covid-19 patients from progressing to acute respiratory distress syndrome or dying. Glenmark plans to release the clinical trial data soon.
You may also be interested in...
While Novartis is continuing to provide hydroxychloroquine for ongoing investigator-initiated trials and support for study of a potential vaccine, it has decided to stop sponsoring hydroxychloroquine clinical trials. Meanwhile, Natco has announced donations of chloroquine phosphate for clinical trials, while Centrient and Beximco have provided PPE for healthcare workers.
The US FDA’s ‘Purple Book’ which was created “to improve transparency and functionality for stakeholders by providing a complete view of biological product options” has been updated after being recently transitioned into an online database.
After launching a biosimilar to Avastin (bevacizumab) in India, Cadila Pharma has now also launched rituximab and teriparatide biosimilars in its domestic market.